Annual Report 2022

CONSOLIDATED STATEMENT OF CASH FLOWS For the year ended 31 December 2022 49 The United Laboratories International Holdings Limited Annual Report 2022 2022 2021 RMB’000 RMB’000 Investing activities Payments for purchase of property, plant and equipment (701,072) (420,251) Payment for deposits of acquisition of property, plant and equipment (78,476) (61,917) Capital contribution of interests in an associate (7,350) – Receipts of commercial bills receivables – 213,905 Proceeds on disposal of property, plant and equipment 7,586 19,164 Placement of pledged bank deposits (3,901,184) (2,551,448) Withdrawal of pledged bank deposits 4,033,869 2,164,253 Placement of financial asset at fair value through profit and loss (1,684,155) – Receipts of financial asset at fair value through profit and loss 1,702,128 – Interest received 70,737 51,594 Receipts of government grants 1,909 2,640 Additions to right-of-use assets (38,911) – Additions to intangible assets – (5,164) Net cash used in investing activities (594,919) (587,224) Financing activities Interest paid (75,615) (50,458) Dividends paid (272,636) (220,847) Capital contribution from the non-controlling interest of a subsidiary 2,000 – Repayments of lease liabilities (3,966) (3,045) New borrowings raised 2,951,824 1,394,373 Repayments of borrowings (2,623,646) (1,709,168) Net settlement of the cross currency interest rate swap (8,160) (3,895) Net settlement of foreign currency forwards 48,324 13,254 Payment on repurchase and cancellation of shares (42,044) (40,978) Transaction costs attributable to repurchase and cancellation of shares (247) (162) Net cash used in financing activities (24,166) (620,926) Net increase in cash and cash equivalents 1,411,458 334,401 Effect of foreign exchange rate changes 604 (194) Cash and cash equivalents at beginning of the year 3,331,009 2,996,802 Cash and cash equivalents at end of the year 4,743,071 3,331,009